CORONA Remedies Limited Q2 FY26 earnings call summary

Earnings call of 5 Jan 2026, summarised by AI from the filing.

CORONA Remedies Q2 FY26 revenue ₹361.1 cr (+15.1% Y-o-Y), PAT ₹52.3 cr (+21.8%), guides 15% revenue and 20% PAT growth for next three to four years.

Key takeaways

1. Guidance 15% revenue growth and 20% PAT or EPS growth for next three to four years.
2. Change Maiden earnings call after listing on 15 December 2025; results published within 21 days.
3. Driver Chronic and semi-chronic segment contributes approximately 70% of total revenues, driving volume growth.
4. Risk Hormonal plant commercial start and approvals depend on EU GMP inspection dates from Hungary.

Original filing on BSE

CORONA Remedies Limited Q1 FY27 results

As filed: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
• Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +2.5% in 28 days (Nifty 500: −4.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

CORONA Remedies Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (3 Aug 2026), Results deck (31 Jul 2026), Results press release (31 Jul 2026)
• Q4 FY26: Earnings call (12 May 2026), Results deck (11 May 2026), Results press release (11 May 2026)
• Q3 FY26: Earnings call (3 Feb 2026), Results deck (2 Feb 2026), Results press release (2 Feb 2026)
• Q2 FY26: Earnings call (5 Jan 2026), Results deck (3 Jan 2026), Results press release (2 Jan 2026)